Open Access<p>Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma</p>
Author(s) -
Yizhen Liu,
Yumei Liu,
Ping Zhao,
Qunling Zhang,
Xiaojian Liu,
Fangfang Lv,
Xin Hong,
Junning Cao,
Kai Xue
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s260974
Subject(s) - medicine , rituximab , vincristine , chop , perforation , gastroenterology , diffuse large b cell lymphoma , lymphoma , surgery , cyclophosphamide , oncology , chemotherapy , materials science , punching , metallurgy
Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common subtype of extranodal non-Hodgkin lymphoma (NHL), with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as the commonly used treatment regimen. However, full cycles of standard R-CHOP present the risk of severe bleeding or perforation, even leading to emergency surgery, especially for those with deep lesions in their first 1-2 cycles of treatment. This study aims to explore the safety and efficacy of fractioned R-CHOP (rituximab d0, 50% dose of CHOP d1 and d5) followed by standard R-CHOP cycles in PG-DLBCL patients guided by endoscopic ultrasonography (EUS).